(Q43591040)

25 November 2017

Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine (English)

1 reference

25 November 2017

1 reference

B Olsson

1

1 reference

PubMed ID

11327200

25 November 2017

J Szamosi

series ordinal

2

1 reference

25 November 2017

1 January 2001

1 reference

Clinical Pharmacokinetics

25 November 2017

1 reference

25 November 2017

40

1 reference

25 November 2017

3

1 reference

25 November 2017

227-235

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200140030-00006

25 November 2017

0 references

cites work

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

12 December 2020

Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine

1 reference

12 December 2020

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

12 December 2020

Food increases the bioavailability of tolterodine but not effective exposure

1 reference

12 December 2020

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry

1 reference

12 December 2020

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

12 December 2020

Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease

1 reference

12 December 2020

Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients

1 reference

12 December 2020

Circadian variation in gastric emptying of meals in humans

1 reference

12 December 2020

Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes

1 reference

12 December 2020

Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects

1 reference

12 December 2020

Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder

1 reference

12 December 2020

Serum protein binding of tolterodine and its major metabolites in humans and several animal species

1 reference

12 December 2020

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

1 reference

12 December 2020

10.2165/00003088-200140030-00006

Identifiers

DOI

1 reference

PubMed ID

11327200

Dimensions Publication ID

25 November 2017

0 references

1 reference

PubMed ID

11327200